The histology and cytology market are involved in the diagnosis of various chronic disease conditions such as cancer, infectious diseases, and others through microscopy procedures conducted on body fluids and tissues. The histology tests involve examining tissues at a microscopic level which helps to diagnose conditions like cancer at an early stage by identifying abnormalities in cells or tissues. Whereas, cytology tests examine body fluids such as blood, urine, or sputum under a microscope to identify abnormalities and signs of diseases like infections or cancer. The rising burden of chronic diseases globally especially cancer is one of the major market drivers. According to WHO, cancer burden rose to 19.3 million new cases and 10 million cancer deaths in 2020 worldwide. This high prevalence of cancer necessitates effective diagnostic procedures like histology and cytology tests for early detection and management of the disease.
Global Histology and Cytology Market is estimated to be valued at US$18528.42 Mn in 2024 and is expected to exhibit a CAGR of 14.% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the histology and cytology market are Abbott, Hologic Inc., Becton, Dickinson and Company, Southwest Precision Instruments, LLC, F. Hoffmann-La Roche Ltd, Sysmex Corporation, Thermo Fisher Scientific Inc., Danaher, Life Technologies Corporation, Merck KGaA, Koninklijke Philips N.V., Perkin Elmer, and Trivitron Healthcare. These players are focusing on new product launches, mergers, acquisitions and geographic expansions to gain maximum market share.
The key opportunities in the histology and cytology market include automation and digitalization of workflow processes for higher efficiency and productivity. Emerging economies with growing healthcare infrastructure and increasing disposable income also present lucrative growth prospects.
Globally, the histology and cytology market is expected to witness high growth in the Asia Pacific region owing to rising awareness, healthcare reforms, and growing prevalence of chronic diseases. Major players are expanding their geographical footprint in high growth regions to tap the business opportunities.
Market drivers: Rising global burden of chronic diseases especially cancer is a major market driver. According to WHO, cancer burden rose to 19.3 million new cases and 10 million cancer deaths in 2020 worldwide. This necessitates effective early diagnostic techniques like histology and cytology tests.
Market restrain: High cost of advanced instrumentation and lack of reimbursement policies in developing nations are some of the factors impeding the histology and cytology market growth. Also, dearth of pathologists and technicians impacts the timely diagnosis and overall market growth.
Segment Analysis
This market can be segmented on the basis of technology into histology technology and cytology technology. The histology technology segment is currently dominating due to rise in prevalence of chronic diseases and cancers that require tissue sample analysis. Histopathology helps in effective disease diagnosis and prognosis. Additionally, automation and digitization in histology sample examination has propelled demand for advanced digital pathology platforms.
Global Analysis
North America holds the largest share in the histology and cytology market due to high adoption of advanced technologies, large prevalence of cancer and chronic diseases, presence of key players and funding opportunities for R&D. Increasing healthcare expenditure and awareness levels also contribute to market growth. Asia Pacific is expected to witness fastest growth during forecast period owing to rise in medical tourism, improving healthcare infrastructure and increasing healthcare spending in developing countries like India and China. Rising geriatric population susceptible to chronic diseases and growing number of diagnostic centres will drive regional market over coming years.
No comments:
Post a Comment